Baidu
map

Nat Struct Mol Biol:内含子RNA调节EZH2表观遗传调控

2012-06-17 bo 生物谷

6月3日,Nature Structural & Molecular Biology杂志报道了内含子RNA调节组蛋白赖氨酸N端甲基转移酶EZH2表观遗传调控的最新进展。 在基因组许多位点的表观遗传修饰异常是肿瘤的一个重要特征。有观点认为,某些RNA分子可指导抑制性多梳蛋白复合物(PRC2)到达特定的染色质区域。 研究者利用体内交叉连接手段在肿瘤细胞中检测和确定PRC2-RNA直接相互作

6月3日,Nature Structural & Molecular Biology杂志报道了内含子RNA调节组蛋白赖氨酸N端甲基转移酶EZH2表观遗传调控的最新进展。

在基因组许多位点的表观遗传修饰异常是肿瘤的一个重要特征。有观点认为,某些RNA分子可指导抑制性多梳蛋白复合物(PRC2)到达特定的染色质区域。

研究者利用体内交叉连接手段在肿瘤细胞中检测和确定PRC2-RNA直接相互作用,发现了许多能结合组蛋白赖氨酸N端甲基转移酶EZH2核心成分的内含子RNA序列。这些序列可调节基因组中EZH2序列的转录产出。H3K4甲基转移酶基因SMYD3具有EZH2结合的内含子RNA。该内含子RNA的过表达伴有EZH2在其相应基因组片段上结合的增加。该内含子RNA的过表达足以降低内源转录物及蛋白的减少,导致培养细胞和动物模型的生长能力的降低。

这些发现表明,内含子RNA在转录水平精细调节基因表达中发挥重要作用。(生物谷bioon.com)

doi:10.1016/j.cell.2011.10.017
PMC:

PMID:

Intronic RNAs mediate EZH2 regulation of epigenetic targets

Sònia Guil,1 Marta Soler,1 Anna Portela,1 Jordi Carrère,1 Elena Fonalleras,1 Antonio Gómez,1 Alberto Villanueva2 & Manel Esteller1, 3,

Epigenetic deregulation at a number of genomic loci is one of the hallmarks of cancer. A role for some RNA molecules in guiding repressive polycomb complex PRC2 to specific chromatin regions has been proposed. Here we use an in vivo cross-linking method to detect and identify direct PRC2-RNA interactions in human cancer cells, revealing a number of intronic RNA sequences capable of binding to the core component EZH2 and regulating the transcriptional output of its genomic counterpart. Overexpression of EZH2-bound intronic RNA for the H3K4 methyltransferase gene SMYD3 is concomitant with an increase in EZH2 occupancy throughout the corresponding genomic fragment and is sufficient to reduce levels of the endogenous transcript and protein, resulting in reduced growth capability in cell culture and animal models. These findings reveal the role of intronic RNAs in fine-tuning gene expression regulation at the level of transcriptional control.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1916897, encodeId=8acb191689e4b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 29 17:03:00 CST 2013, time=2013-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795116, encodeId=7cc21e9511659, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Jan 01 23:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766786, encodeId=85321e6678632, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 29 01:03:00 CST 2013, time=2013-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746900, encodeId=5d2c1e469007b, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 03 06:03:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812745, encodeId=469f1812e45cb, content=<a href='/topic/show?id=8589902631e' target=_blank style='color:#2F92EE;'>#表观遗传调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90263, encryptionId=8589902631e, topicName=表观遗传调控)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed May 08 10:03:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879273, encodeId=9b6518e92737f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 21 10:03:00 CST 2012, time=2012-10-21, status=1, ipAttribution=)]
    2013-04-29 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1916897, encodeId=8acb191689e4b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 29 17:03:00 CST 2013, time=2013-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795116, encodeId=7cc21e9511659, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Jan 01 23:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766786, encodeId=85321e6678632, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 29 01:03:00 CST 2013, time=2013-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746900, encodeId=5d2c1e469007b, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 03 06:03:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812745, encodeId=469f1812e45cb, content=<a href='/topic/show?id=8589902631e' target=_blank style='color:#2F92EE;'>#表观遗传调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90263, encryptionId=8589902631e, topicName=表观遗传调控)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed May 08 10:03:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879273, encodeId=9b6518e92737f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 21 10:03:00 CST 2012, time=2012-10-21, status=1, ipAttribution=)]
    2013-01-01 日月
  3. [GetPortalCommentsPageByObjectIdResponse(id=1916897, encodeId=8acb191689e4b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 29 17:03:00 CST 2013, time=2013-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795116, encodeId=7cc21e9511659, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Jan 01 23:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766786, encodeId=85321e6678632, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 29 01:03:00 CST 2013, time=2013-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746900, encodeId=5d2c1e469007b, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 03 06:03:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812745, encodeId=469f1812e45cb, content=<a href='/topic/show?id=8589902631e' target=_blank style='color:#2F92EE;'>#表观遗传调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90263, encryptionId=8589902631e, topicName=表观遗传调控)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed May 08 10:03:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879273, encodeId=9b6518e92737f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 21 10:03:00 CST 2012, time=2012-10-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1916897, encodeId=8acb191689e4b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 29 17:03:00 CST 2013, time=2013-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795116, encodeId=7cc21e9511659, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Jan 01 23:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766786, encodeId=85321e6678632, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 29 01:03:00 CST 2013, time=2013-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746900, encodeId=5d2c1e469007b, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 03 06:03:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812745, encodeId=469f1812e45cb, content=<a href='/topic/show?id=8589902631e' target=_blank style='color:#2F92EE;'>#表观遗传调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90263, encryptionId=8589902631e, topicName=表观遗传调控)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed May 08 10:03:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879273, encodeId=9b6518e92737f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 21 10:03:00 CST 2012, time=2012-10-21, status=1, ipAttribution=)]
    2012-08-03 fusion
  5. [GetPortalCommentsPageByObjectIdResponse(id=1916897, encodeId=8acb191689e4b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 29 17:03:00 CST 2013, time=2013-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795116, encodeId=7cc21e9511659, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Jan 01 23:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766786, encodeId=85321e6678632, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 29 01:03:00 CST 2013, time=2013-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746900, encodeId=5d2c1e469007b, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 03 06:03:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812745, encodeId=469f1812e45cb, content=<a href='/topic/show?id=8589902631e' target=_blank style='color:#2F92EE;'>#表观遗传调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90263, encryptionId=8589902631e, topicName=表观遗传调控)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed May 08 10:03:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879273, encodeId=9b6518e92737f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 21 10:03:00 CST 2012, time=2012-10-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1916897, encodeId=8acb191689e4b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 29 17:03:00 CST 2013, time=2013-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795116, encodeId=7cc21e9511659, content=<a href='/topic/show?id=1c9f16846fe' target=_blank style='color:#2F92EE;'>#Struc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16846, encryptionId=1c9f16846fe, topicName=Struc)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Tue Jan 01 23:03:00 CST 2013, time=2013-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766786, encodeId=85321e6678632, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 29 01:03:00 CST 2013, time=2013-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746900, encodeId=5d2c1e469007b, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 03 06:03:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812745, encodeId=469f1812e45cb, content=<a href='/topic/show?id=8589902631e' target=_blank style='color:#2F92EE;'>#表观遗传调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90263, encryptionId=8589902631e, topicName=表观遗传调控)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed May 08 10:03:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879273, encodeId=9b6518e92737f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 21 10:03:00 CST 2012, time=2012-10-21, status=1, ipAttribution=)]
    2012-10-21 liye789132251

相关资讯

PNAS:癌症起源的新线索

不同类型肿瘤的产生依赖于DNA损伤效应、细胞周期关键点以及凋亡的特定蛋白质的突变。(Credit: Image courtesy of Institute for Research in Biomedicine-IRB) 近日,来自巴塞罗那生物医药研究所(IRBB)和斯隆凯特琳癌症研究中心(MSKCC)的研究者揭示了癌症起源新的研究信息,这项研究刊登在了国际著名杂志PNAS上。文章中,研究者表示

Cancer Res:纤蛋白-3激活Notch通路促进神经胶质细胞瘤恶性

6月4日Cancer Research杂志在线报道了纤蛋白-3促进肿瘤侵袭的机制研究新发现。纤蛋白-3是一种不存在于正常大脑,而在神经胶质细胞瘤中显著上调的基质蛋白。其促进肿瘤侵袭的机制不明。恶性神经胶质细胞瘤是高侵袭性、化疗抵抗性脑瘤,预后极差。浸润性神经胶质细胞瘤细胞是复发的主要来源。针对触发侵袭和化疗抵抗的可溶性因子,也许可以对这类癌细胞有显著的抑制效果。 这项研究揭示:纤蛋白-3作为No

Nat Rev Cancer:科学家揭示转录因子Cut调控作用

近日,国际著名评论杂志Nature Reviews Cancer在线刊登了一篇评论文章“Tumorigenesis: Cut here for differentiation,”,文章揭示了转录因子Cut的功能。扰乱分化与细胞凋亡的调节已知促进了癌症的发展,但这两个过程之间的关联却一直没有搞清。Ingrid Lohmann和同事如今发现了几个重要的信号通道,通过转录因子Cut(被ct所编码)来调节

AJP:陈策实等乳腺癌Hippo信号通路研究获进展

雌激素受体ER阴性乳腺癌是一种恶性程度比较高的乳腺癌类型,关于此类乳腺癌的信号通路研究一直是癌症研究领域长期未曾透彻解决的问题。近年来大量文章证实Hippo信号通路与乳腺细胞的增殖和凋亡有着重要关系。Hippo信号通路的下游主要通过YAP/TAZ共转录因子结合其它转录因子调控基因表达来实现,目前普遍认为YAP/TAZ结合的主要转录因子是TEADs以及含有PY序列的几个转录因子如Smads、RUNX

Blood:药物组合疗法有助治疗多发性骨髓瘤

三种药物治疗为一种血癌类型--多发性骨髓瘤提供了快速,深刻的和潜在的持久的反应,研究人员将最新研究论文发表在Blood杂志上。 芝加哥大学医学中心的主任医师Andrzej J. Jakubowiak博士带领研究人员发现相比原于一线治疗方案,carfilzomib(新一代蛋白酶抑制剂)联合lenalidomide和低剂量地塞米松治疗多发性骨髓瘤效果更好。 Jakubowiak说:这些迅速和持久的

Cancer Res.:多梳蛋白EZH2调节肿瘤演进和转移

在人类肿瘤转移中,表观遗传修饰发挥着重要作用。5月30日Cancer Research 杂志发表了Gang Ren等人的研究论文,更加深了人类对这一问题的认识。 Zeste 同源序列2的增强子EZH2,编码多梳蛋白抑制复合体2(PRC2)中甲基转移酶的成分。EZH2在乳腺癌、前列腺癌中广泛过表达,并可以表观遗传修饰的方式沉默肿瘤抑制因子的表达。以往研究表明,具有抑癌、抑转移作用的Raf-1激酶抑

Baidu
map
Baidu
map
Baidu
map